Provided by Tiger Trade Technology Pte. Ltd.

Candel Therapeutics, Inc.

12.86
-0.2700-2.06%
Post-market: 12.83-0.0251-0.20%19:57 EDT
Volume:959.09K
Turnover:12.26M
Market Cap:984.03M
PE:-8.94
High:12.99
Open:12.99
Low:12.40
Close:13.13
52wk High:13.82
52wk Low:4.35
Shares:76.52M
Float Shares:60.06M
Volume Ratio:0.58
T/O Rate:1.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4390
EPS(LYR):-0.7210
ROE:-81.84%
ROA:-28.64%
PB:7.80
PE(LYR):-17.84

Loading ...

Has Candel Therapeutics (CADL) Run Too Far Ahead On Widening Losses?

Simply Wall St.
·
Yesterday

Candel Therapeutics CTO Seshu Tyagarajan Sells 7,000 Shares for $84,000

Reuters
·
Aug 20

Candel Therapeutics is Maintained at Neutral by B of a Securities

Dow Jones
·
Aug 15

Analysts Are Bullish on Top Healthcare Stocks: Candel Therapeutics (CADL), Acurx Pharmaceuticals (ACXP)

TIPRANKS
·
Aug 14

BofA Adjusts Price Target on Candel Therapeutics to $12 From $9

MT Newswires Live
·
Aug 14

Analysts Have Conflicting Sentiments on These Healthcare Companies: Candel Therapeutics (CADL), LENSAR (LNSR) and Pyxis Oncology (PYXS)

TIPRANKS
·
Aug 14

Candel Therapeutics Price Target Maintained with a $23.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 14

Candel Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

Earnings Flash (CADL) Candel Therapeutics Posts Q2 Net Loss $0.52 a Share, vs. FactSet Est of $0.21 Loss

MT Newswires Live
·
Aug 13

Candel Therapeutics: Q2 EPS $-0.52

THOMSON REUTERS
·
Aug 13

Candel Therapeutics Q2 FY26 Net Loss Widens to $38.9 Million; R&D Expense More than Doubles to $19.8 Million

Reuters
·
Aug 13

Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

THOMSON REUTERS
·
Aug 13

Candel Therapeutics Inc Expected to Post a Loss of 24 Cents a Share - Earnings Preview

Reuters
·
Aug 10

Candel Therapeutics Grants Inducement Stock Options for 30,800 Shares at $10.01 Each

Reuters
·
Aug 04

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 04

Candel Therapeutics to Present Extended Phase 3 Data on Aglatimagene Besadenovec in Localized Prostate Cancer at ASTRO 2026

Reuters
·
Aug 03

Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston

GlobeNewswire
·
Jul 29

Candel Therapeutics Inc : Stifel Initiates Coverage with Buy Rating; Target Price $22

THOMSON REUTERS
·
Jul 13

Candel Therapeutics Initiated at Buy by Stifel

Dow Jones
·
Jul 13

Candel Therapeutics initiated with a Buy at Stifel

TIPRANKS
·
Jul 13